Literature DB >> 23586913

Selection and in vitro characterization of human CD44v6-binding antibody fragments.

Johan Nilvebrant1, Gamze Kuku, Hanna Björkelund, Marika Nestor.   

Abstract

The cluster of differentiation (CD) 44v6 antigen has been suggested to be involved in tumor formation, invasion, and metastasis formation, and has been observed in a majority of primary and metastatic squamous cell carcinomas of the head and neck. Probes specifically binding to this region may be utilized as tools for the challenging tasks of early detection and targeted treatments of small residual disease. In this project, an epitope-guided phage display selection of human fragment antigen-binding (Fab) fragments with affinity to the v6 sequence was performed. A selected set of Fab fragments was shown to specifically recognize increasingly complex forms of the target sequence, both in the form of a short synthetic or recombinant peptide and in the context of a purified extracellular domain of CD44. The binding was independent of known v6-sequence variation and posttranslational modifications that are common in the CD44 protein family. Furthermore, real-time interaction measurements on antibody fragments labeled with ¹²⁵I showed specific and high-affinity binding to the antigen present on cultured head and neck squamous cell carcinoma cells. There was no cross-reactivity toward cells that lack the target protein. As hypothesized, characterization of the interaction between Fab fragments and the targets using the mathematical tool Interaction Map revealed more heterogeneous interactions on cells than with pure proteins analyzed by surface plasmon resonance. One main candidate Fab fragment with optimal affinity for all forms of the target sequence was identified. The flexible recombinant source of the Fab fragments might aid the development of tailored molecules adapted for therapeutic or diagnostic applications in the future.
© 2012 International Union of Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23586913     DOI: 10.1002/bab.1033

Source DB:  PubMed          Journal:  Biotechnol Appl Biochem        ISSN: 0885-4513            Impact factor:   2.431


  11 in total

1.  Evaluating real-time immunohistochemistry on multiple tissue samples, multiple targets and multiple antibody labeling methods.

Authors:  Louise Dubois; Karl Andersson; Anna Asplund; Hanna Björkelund
Journal:  BMC Res Notes       Date:  2013-12-18

2.  Deciphering the stepwise binding mode of HRG1β to HER3 by surface plasmon resonance and interaction map.

Authors:  Carmen Peess; Leopold von Proff; Sabine Goller; Karl Andersson; Michael Gerg; Magnus Malmqvist; Birgit Bossenmaier; Michael Schräml
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

3.  Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model.

Authors:  Diana Spiegelberg; Anja C Mortensen; Ram K Selvaraju; Olof Eriksson; Bo Stenerlöw; Marika Nestor
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-01       Impact factor: 9.236

Review 4.  CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches.

Authors:  Diana Spiegelberg; Johan Nilvebrant
Journal:  Contrast Media Mol Imaging       Date:  2017-06-20       Impact factor: 3.161

5.  New approaches for the reliable in vitro assessment of binding affinity based on high-resolution real-time data acquisition of radioligand-receptor binding kinetics.

Authors:  Markus Zeilinger; Florian Pichler; Lukas Nics; Wolfgang Wadsak; Helmut Spreitzer; Marcus Hacker; Markus Mitterhauser
Journal:  EJNMMI Res       Date:  2017-03-07       Impact factor: 3.138

6.  Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers.

Authors:  Anna-Karin Haylock; Johan Nilvebrant; Anja Mortensen; Irina Velikyan; Marika Nestor; Ronny Falk
Journal:  Oncotarget       Date:  2017-05-18

7.  Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2.

Authors:  Anja C L Mortensen; Eric Morin; Christopher J Brown; David P Lane; Marika Nestor
Journal:  EJNMMI Res       Date:  2020-04-16       Impact factor: 3.138

8.  In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma: a dual-isotope study.

Authors:  Anna-Karin Haylock; Diana Spiegelberg; Johan Nilvebrant; Karl Sandström; Marika Nestor
Journal:  EJNMMI Res       Date:  2014-03-06       Impact factor: 3.138

9.  Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma.

Authors:  Anna-Karin Haylock; Diana Spiegelberg; Anja C Mortensen; Ram K Selvaraju; Johan Nilvebrant; Olof Eriksson; Vladimir Tolmachev; Marika V Nestor
Journal:  Int J Oncol       Date:  2015-12-14       Impact factor: 5.650

Review 10.  Development of therapeutic antibodies for the treatment of diseases.

Authors:  Ruei-Min Lu; Yu-Chyi Hwang; I-Ju Liu; Chi-Chiu Lee; Han-Zen Tsai; Hsin-Jung Li; Han-Chung Wu
Journal:  J Biomed Sci       Date:  2020-01-02       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.